Literature DB >> 19176944

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.

Staffan Welin1, Mats Stridsberg, Janet Cunningham, Dan Granberg, Britt Skogseid, Kjell Oberg, Barbro Eriksson, Eva T Janson.   

Abstract

BACKGROUND: Patients with malignant midgut carcinoids are occasionally diagnosed with limited tumor spread, and surgery with radical intention is performed. Despite curative intent, recurrences occur frequently, motivating long-term biochemical and radiological follow-up. This study aimed to compare the usefulness of various methods in detecting such recurrences.
METHODS: This retrospective study included 56 patients with radically operated midgut carcinoids referred to our University Hospital for evaluation and follow-up between 1985 and 2004. Patients were monitored 1-3 times per year using plasma-chromogranin A (P-CgA), urinary 5-hydroxyindoleacetic acid (U-5HIAA) concentrations as well as radiological examinations, including ultrasonography, computerized tomography or magnetic resonance investigation. In a subset of cases, somatostatin receptor scintigraphy and/or positron emission tomography with 5-hydroxytryptophan was performed. Time from operation until established recurrence was recorded.
RESULTS: Tumor recurrence was established in 33 of 56 patients after a median of 32 months (range 6-217). Elevated P-CgA was the first marker to become pathologically elevated in 28 of these 33 patients (85%). In 3 of these 28 patients, radiology was simultaneously positive for a recurrence.
CONCLUSION: P-CgA was the first marker to indicate tumor recurrence in the majority of radically operated midgut carcinoid patients. To avoid unnecessary and costly examinations in asymptomatic patients, we suggest that follow-up should comprise measurements of P-CgA twice a year and annual ultrasonography until P-CgA is elevated or clinical symptoms occur, at which time all efforts should be made to identify recurrent tumor lesions in order to give the patient the best possible treatment which, if possible, should be surgical removal of the recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176944     DOI: 10.1159/000179900

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  22 in total

1.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 2.  The use of biomarkers in neuroendocrine tumours.

Authors:  Mohid Shakil Khan; Martyn E Caplin
Journal:  Frontline Gastroenterol       Date:  2013-03-21

Review 3.  Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas
Journal:  Endocrine       Date:  2011-11-29       Impact factor: 3.633

4.  Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.

Authors:  Giovanni Gori; Giacomo Spinelli; Claudio Spinelli; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

5.  Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.

Authors:  Ken Herrmann; Johannes Czernin; Edward M Wolin; Pawan Gupta; Martin Barrio; Antonio Gutierrez; Christiaan Schiepers; Sherly Mosessian; Michael E Phelps; Martin S Allen-Auerbach
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

6.  Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours.

Authors:  Roberta Elisa Rossi; Jorge Garcia-Hernandez; Tim Meyer; Christina Thirlwell; Jennifer Watkins; Nicholas Guy Martin; Martyn Evan Caplin; Christos Toumpanakis
Journal:  Ann Transl Med       Date:  2015-06

Review 7.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

8.  A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.

Authors:  Ivan Kruljac; Ivan Vurnek; Sebastian Maasberg; Davor Kust; Kristina Blaslov; Blaženka Ladika Davidović; Mario Štefanović; Alma Demirović; Alen Bišćanin; Jakša Filipović-Čugura; Jasmina Marić Brozić; Ulrich-Frank Pape; Milan Vrkljan
Journal:  Endocrine       Date:  2018-04-09       Impact factor: 3.633

9.  A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.

Authors:  Magnus Kjellman; Ulrich Knigge; Staffan Welin; Espen Thiis-Evensen; Henning Gronbaek; Camilla Schalin-Jäntti; Halfdan Sorbye; Maiken Thyregod Joergensen; Viktor Johanson; Saara Metso; Helge Waldum; Jon Arne Søreide; Tapani Ebeling; Fredrik Lindberg; Kalle Landerholm; Goran Wallin; Farhad Salem; Maria Del Pilar Schneider; Roger Belusa
Journal:  Neuroendocrinology       Date:  2020-07-28       Impact factor: 4.914

10.  Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.

Authors:  Tao Cui; Monica Hurtig; Graciela Elgue; Su-Chen Li; Giulia Veronesi; Ahmed Essaghir; Jean-Baptiste Demoulin; Giuseppe Pelosi; Mohammad Alimohammadi; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.